Company profile

Ticker
CLDX
Exchange
Website
CEO
Anthony S. Marucci
Employees
Incorporated
Location
Fiscal year end
Former names
AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
SEC CIK
IRS number
133191702

CLDX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Nov 20
27 Nov 20
31 Dec 20

News

Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
18 Jun 20 Shoos Karen L. NQSO Common Stock Grant Aquire A No 10.38 11,000 114.18K 11,000
18 Jun 20 Penner Harry JR NQSO Common Stock Grant Aquire A No 10.38 11,000 114.18K 11,000
18 Jun 20 Pepin Ronald Incentive Stock Option Common Stock Grant Aquire A No 10.38 14,400 149.47K 14,400
18 Jun 20 Wright Richard M. Incentive Stock Option Common Stock Grant Aquire A No 10.38 42,000 435.96K 42,000
18 Jun 20 Young Diane C. Incentive Stock Option Common Stock Grant Aquire A No 10.38 72,000 747.36K 72,000
81.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 91 74 +23.0%
Opened positions 36 39 -7.7%
Closed positions 19 8 +137.5%
Increased positions 25 12 +108.3%
Reduced positions 13 9 +44.4%
13F shares
Current Prev Q Change
Total value 470.29M 356.45M +31.9%
Total shares 31.71M 27.42M +15.7%
Total puts 205.2K 211.7K -3.1%
Total calls 454.3K 795K -42.9%
Total put/call ratio 0.5 0.3 +69.6%
Largest owners
Shares Value Change
RTW Investments 3.12M $46.27M +19.5%
BVF 3.07M $45.48M +11.9%
Adage Capital Partners GP, L.L.C. 2.05M $30.4M +17.1%
Redmile 1.99M $29.5M -0.5%
Renaissance Technologies 1.74M $25.76M +6.1%
Vanguard 1.72M $25.56M +33.0%
Vivo Capital 1.72M $25.55M +7.7%
Acuta Capital Partners 1.55M $22.91M +54.5%
Ikarian Capital 1.47M $21.8M -10.8%
POLR Polar Capital 1.25M $18.54M NEW
Largest transactions
Shares Bought/sold Change
POLR Polar Capital 1.25M +1.25M NEW
VR Adviser 800K +800K NEW
Logos Global Management 1.2M -800K -40.0%
Ra Capital Management 353.07K -796.93K -69.3%
Eversept Partners 150.49K -562.2K -78.9%
Acuta Capital Partners 1.55M +545K +54.5%
IVZ Invesco 534.58K +534.58K NEW
RTW Investments 3.12M +510.14K +19.5%
Corriente Advisors 0 -460K EXIT
Millennium Management 0 -430.56K EXIT

Financial report summary

?
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: administered, Answer, award, awarded, baseline, breach, capacity, case, Chancery, closely, closing, Complaint, Connemara, contact, Counterclaim, Court, covenant, dealing, declaratory, dedicated, Delaware, disagree, enrichment, evolving, Germany, hired, intravenously, LLC, matter, METRIC, minimize, National, NIH, partnership, percentage, pharmacodynamic, pharmacokinetic, proper, properly, provocation, real, satisfy, SBIR, screened, Shareholder, situation, skin, Small, sought, SRS, unjust, valid, Verified, vi
Removed: addressing, aimed, antitumor, ASCO, biomarker, breast, CBR, cetuximab, checkpoint, diarrhea, DOR, emerging, endpoint, Erbitux, expanded, extension, focused, futility, gastric, HPV, initiate, melanoma, objective, ORR, OS, partial, PFS, poor, rash, regulating, resistance, selection, Simon, somatic, thyroid, treat, uPR, utility

Patents

APP
Utility
Agonistic Antibodies That Bind Human CD40 and Uses Thereof
26 Nov 20
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
GRANT
Utility
Methods of treating by administering anti-kit antibodies
6 Oct 20
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies.
GRANT
Utility
Methods of treating by administering anti-kit antibodies
22 Sep 20
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies.
GRANT
Utility
Treatment of eosinophil or mast cell related disorders
15 Sep 20
Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).
GRANT
Utility
Anti-ErbB antibodies and methods of use thereof
18 Aug 20
Provided herein are compositions, methods and uses involving antibodies that bind to ErbB, a receptor tyrosine kinase, and modulate the activity of ErbB.